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Abstract
Thyroid hormones play a critical role in brain development but also in the adult human brain by modulating
metabolic activity. Hypothyroid states are associated with both functional and structural brain alterations also seen
in patients with major depression. Recent animal experimental and preclinical data indicate subtle changes in
myelination, microvascular density, local neurogenesis, and functional networks. The translational validity of such
studies is obviously limited. Clinical evidence for neurobiological correlates of different stages and severities of
hypothyroidism and effects of pharmacological intervention is lacking but may be achieved using advanced
imaging techniques, e.g. functional and quantitative MRI techniques applied to patients with hypothyroidism
before and after hormone replacement therapy.
Introduction
The profound influence of thyroid hormones on brain
development in humans has been studied extensively
[1-6]. Hypothyroidism is a clinical condition which is
either characterized only by elevated levels of the thyr-
oid stimulating hormone (TSH; “subclinical hypothyr-
oidism”) or additional low levels of trijodothyronine
(T3) and thyroxin (T4) respectively (overt hypothyroid-
ism). Taken together overt (0.4%) and subclinical (9%)
hypothyroisism is prevalent in about 9.4 % of the adult
population [7] and commonly affects brain function.
Conversely, 15% of patients with depression display
hypothyroid states including subclinical hypothyroidism
[8], and about 25-30% of depressed patients show a
pathological response to the thyreotropine releasing hor-
mone (TRH) stimulation test [9].
The concepts of thyroid hormone action in the adult
brain have changed dramatically along with rapid
advances in basic science and methodological techniques
over the past decades [10]. Particularly brain imaging
techniques evaluating cerebral metabolism, perfusion,
and anatomy enabled encouraging insights into the thyr-
oid-brain relationship. As a result, it is now widely
accepted that thyroid hormones play a critical role in
the adult brain impacting mood and cognition. Even if
crucial details of the underlying mechanisms still remain
unknown [11], the therapeutic use of thyroid hormones
in the clinical treatment of mood disorders has already
been established in predominantly open trials with
sometimes limited numbers of patients.
Thyroid hormone treatment has been shown to accel-
erate and augment antidepressant pharmacotherapy and
to support maintenance therapy of bipolar affective dis-
orders, even in patients with euthyroid hormonal state
[10,12]. Specifically, there is good evidence that tri-
jodthyronine (T3) can accelerate [13] and augment [14]
the therapeutic response to tricyclic antidepressants and
selective serotonin reuptake inhibitors (SSRIs) in
depression.
Adjunctive treatment with supraphysiological doses of
Levothyroxine (T4) was found to be effective in open
clinical studies of patients with affective disorders
[15-18]. In a subset of 21 patients with treatment-resis-
tant affective disorder, very high doses of up to 600 μg
per day L-T4 were required to achieve therapeutic
response with a good tolerability even over mean treat-
ment periods of up to 51 month [16].
In the first double-blind randomized placebo-con-
trolled trial (RCT) to evaluate efficacy and tolerability of
supraphysiological doses of L-T4 in 63 patients, we
found that bipolar depressed women treated with L-T4
showed a better improvement in depression scores than
those treated with placebo. However including both gen-
ders, the study failed to detect an overall
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statistically significant treatment effect (Stamm et al., in
preparation).
Brain imaging methods
Principal brain imaging techniques mentioned in this
article are single photon emission computed tomogra-
phy (SPECT), positron emission tomography (PET), and
different methods of magnetic resonance imaging (MRI).
PET and SPECT are nuclear imaging methods that
require the injection of radioactive tracers into the cir-
culatory system. Those tracers bind to molecular struc-
tures like transporters and receptors in the human
brain. Measuring of the local distribution of the bound
tracers allows an estimation of regional brain activation
or availability of receptors. The glucose analog [18F]-
Fluor-2-Desoxy-D-Glucose (FDG) is by far the most
commonly used PET tracer and its metabolism reflects
the amount of brain activity in different brain regions.
In contrast to these nuclear imaging methods, MRI is
non-invasive and uses magnetic fields and radio waves
instead of ionizing radiation. Structural MRI methods
allow creating images of anatomical structures in an
excellent spatial resolution (less than 1 mm). Diffusion
tensor imaging (DTI) characterizes the mobility of water
molecules and, thus, the directionality and integrity of
white matter tracts. Magnetization transfer (MT) is sen-
sitive to myelin content and is therefore useful in
detecting early demyelination processes.
Functional magnetic resonance imaging (fMRI) has
become the tool of choice to study functional aspects of
the human brain. This method detects local increases of
blood flow and the following decrease of deoxygenated
hemoglobin during task related brain activity. The signal
measured directly relies on the so-called BOLD (blood
oxygen level dependent) effect. It is based on the differ-
ent magnetic properties of oxygenated and deoxygenated
hemoglobin. The origin of the BOLD signal is still a
matter of discussion as it is also based on the complex
interaction of neuronal metabolism, neuronal activity,
blood flow and blood volume. Nevertheless fMRI
enables the monitoring of active neuronal networks dur-
ing the performance of specific paradigms, e.g. a mem-
ory task. Related to affective disorders, MRI allows the
investigation of functional and structural deficits asso-
ciated with neuropsychiatric symptoms as well as treat-
ment effects.
Major advantages of neuroimaging methods are that
brain structure and function as well as molecular and
neurochemical processes can be studied in the living
human. An important limitation of the mentioned brain
imaging techniques refers to temporal resolution. While
neuronal activities occur in the range of milliseconds,
processes detected by imaging methods currently ranges
between seconds (fMRI) and minutes (PET).
Additionally, all methods measure brain activity indir-
ectly through changes in blood flow or glucose uptake.
Consequently, alterations in baseline perfusion and
metabolic rate of oxygen may affect the results. More-
over it is currently not possible to reliably distinguish
between inhibitory and excitatory neuronal activities.
Nevertheless, given the rapid developments in neuroi-
maging methods; many limitations may hopefully be
overcome in the next decades [19].
Mechanisms of action
On the molecular level, thyroid hormones act via geno-
mic and non-genomic effects. As part of the nuclear
superfamily of ligand-modulated transcription factors,
thyroid hormones bind to intracellular nuclear receptors
[20]. Genomic actions of T3 are mediated through the
control and usually increase of gene expression
[12,21,22]. Genes that are regulated by thyroid hor-
mones are known to encode for proteins such as myelin,
neurotrophins, and proteins that are involved in intra-
cellular signaling pathways [23].
Non-genomic actions of thyroid hormones have been
described in the brain and peripheral tissues. After bind-
ing to cytoplasmic thyroid hormone receptors, T3
appears to be able to rapidly activate the phosphatidyli-
nositol-3-kinase protein pathway and thereby achieves
vasodilatory and neuroprotective effects [24]. Addition-
ally, an increase in serotonergic neurotransmission is
mediated by a thyroid hormone induced reduction of
the sensitivity of 5-HT1A autoreceptors in the raphe
nuclei and increase in 5-HT2 receptor sensitivity
[25,26]. The exact role of these non-genomic signaling
mechanisms, their regulation, and interaction with the
slower genomic pathways remains to be elucidated.
Thyroid hormone homeostasis in the brain underlies a
complex interaction of different autoregulative mechan-
isms [27,28]. The activity of specific thyroid hormone
transporters (MCT8, LAT2) and the carrier transthyre-
tin determines intracellular concentration of thyroid
hormones via mediating their cellular influx and efflux
under consideration of overall circulating levels of T4
and T3[27]. The activity of deiodinases [29,30] controls
local bioavailability of T3 in concert with other less
understood mechanisms, e.g. the local distribution of
the different nuclear thyroid hormone receptors (TRa
and TRb in diverse isoforms) [31]. Thyroid hormone
receptors are widely distributed in the brain with highest
concentrations in cerebral cortex, hippocampus, amyg-
dala, plexus choroideus and olfactory bulb [31].
Interestingly, the limbic structures, where thyroid hor-
mone receptors are prevalent, have repeatedly been
shown to be implicated in the pathogenesis of mood
disorders [32]. However, the neuropharmacological basis
and the functional pathways for the modulatory effects
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of thyroid hormones on mood are yet to be understood,
even though several studies revealed interactions with
different neurotransmitter systems, which are generally
believed to play a major role in the regulation of mood
and behaviour, i.e norepinephrine or serotonine [26,33].
Structural changes induced by hypothyroidism
Thyroid hormones are known to affect neuronal differ-
entiation, migration, myelination, synaptogenesis, and
dendritic branching [8,9,34,35]. Therefore, hypothyroid-
ism will change brain structure and the changes will
depend on the onset time of the condition. Hypothyroid
rodents display a loss of neurons in several brain
regions. Next to the visual cortex [36] and cerebellum
[37], the hippocampal formations were studied repeat-
edly. The number of granule cells in the dentate gyrus
was reduced [38] with a more severe effect of hypothyr-
oidism during development than during adulthood [39].
Rats treated with methimazole, a hypothyroidism indu-
cing drug, showed a reduced count of pyramidal neu-
rons in the CA3 hippocampal region [40]. This was
found even if methimazole was administered in adult-
hood. Animals could be fully protected with T4 replace-
ment and partially protected with T3 replacement [41].
It is speculated that this protective potency is mediated
through the activation of hippocampal progenitor cells
of the supraventricular zone and the dentate gyrus [42].
Mice with a heterozygous mutation of the thyroid hor-
mone receptor alpha 1 showed a reduced density of
GABAergic inhibitory interneurons in the CA1 hippo-
campal region [40]. On the behavioural side, these mice
show increases in markers for depression and anxiety
[43,44]. Both the behavioural measures as well as the
neuronal density normalized with high levels of T3
administered in adulthood. In contrast to the above
findings, hypothyroid rats treated at age 0-30 days with
propylthiouracil (PTU) showed a loss of pyramidal neu-
rons in CA1, which did not ameliorate after withdrawal
of the drug and approximate normalization of serum T4
levels [45]. A thyroidectomy at day 30 also reduced the
number of neurons. The same study reported in CA3 a
volume decrease of the pyramidal layer combined with
an increase in neuronal density and no loss in the total
number of pyramidal neurons. Only one study is known
in this context that applied MRI in rodents [46]. Using
manual segmentation, perinatal hypothyroidism induced
with methimazole administered to mother rats was
found to reduced total brain size of the litter but not
the relative size of the hippocampus.
Effects of T3 and T4 have also been reported in the
process of myelination or remyelination in mice [47,48]
and rats [49,50]. Harsan et al. [48] used Diffusion Ten-
sor Imaging (DTI) in combination with histology to
serve as a marker for remyelination in mice and found
that cuprizone induced demyelination in adulthood was
reversable through treatment with T3, which increased
the number of oligodendrocyte progenitor cells. Using
histology and electronmicroscopy, Franklin and Gilson
[51] found that Schwann cell remyelination was
decreased in thyroidectomized rats but not oligodendro-
cyte remyelination.
While the efficacy of thyroid hormone treatments is
generally accepted, human data on structural changes in
the brain is sparse. Using proton MRS, Jagannathan et
al. [52] found that abnormalities related to myelin
maturation were reversible under T4 therapy in three
mentally disabled patients with congential hypothyroid-
ism. A more recent investigation [53] using similar MRS
and MRI methodology demonstrated general atrophy
and signs of demyelination in two children with mono-
carboxylate transporter 8 (MCT8) gene deficiency,
which is associated with a syndrome combining thyroid
and severe neurological abnormalities.
Systematic group studies of structural brain changes
due to hypothyroidism and thyroid hormone therapy are
needed both during development and in adulthood. In
addition to MRS, recent advances in structural MRI,
quantitative MRI, and image analysis techniques could
be utilized to test hypotheses derived from animal stu-
dies in human. Structural changes related to myelin can
now be studied with quantitative T2 or quantitative
magnetization transfer (MT) imaging [54]. Diffusion
tensor imaging (DTI) can reveal information on white
matter integrity. Changes in grey matter density [55] or
cortical thickness [56,57] can be studied with T1-
weighted images.
Vascular Changes and Perfusion
Thyroid hormones are known to affect the vascular
system. Hypothyroidism is associated with impaired
fibrinolysis and blood coagulation resulting in cerebro-
vascular diseases [58]. It also compromises protective
endothelial [59] and thrombocyte functions as well as
lipid metabolism [60].
In the rat forebrain, a significant reduction in blood
vessel density was observed in untreated rats thyroidec-
tomised shortly after birth compared to euthyroid con-
trol animals and thyroidectomized rats treated with T4
or the thyroid hormone analog 3,5-diiothyroprionic acid
(DITPA) [61]. Treatment induced angiogenesis and
improved functioning of endothelial cells with secondary
impact on local oxygen consumption and metabolic
activity.
PET and SPECT measurements of cerebral blood flow
under consideration of the thyroid system revealed par-
tially conflicting results. Most consistently hypothyroid-
ism was associated with global, diffuse hypoperfusion
[62,63]. Several studies pointed to more regional effects
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including perfusion deficits pronounced in posterior
brain regions [64-66] or in the parietal lobe [63].
Interpretation of the findings regarding reversibility of
perfusion abnormalities under treatment is especially
challenging. Whereas several studies report partial nor-
malization of perfusion [17,62,67], others demonstrate
[64-66] ongoing regional hypoperfusion under hormone
replacement therapy. In contrast to the hypoperfusion
pattern reported for hypothyroidism by Kraus et al. [64]
in otherwise healthy subjects with posterior hypoperfu-
sion and slight hyperperfusion anteriorly, depressed
patients showed hypoperfusion in limbic, subcortical
and frontal brain regions [32], which normalized under
therapy with supraphysiological dosages (300 mcg/day)
of T4.
Differences in the studied populations may be the rea-
son for such variable findings. Published results refer
either to severe cases of hypothyroidism [62,63] or mild
cases [66,68]. Some studies excluded patients with co-
morbid psychiatric diseases like depression [64,68],
while other studies included also depressed patients
[17,69]. In addition, the duration of the disease was vari-
able. Only one study examined populations with varying
severity and duration of the disease [17]. Taken together
the existing data may indicate that long and severe
hypothyroidism, presumably leading to irreversible
structural neuronal and vascular changes, is associated
with chronic perfusion and functional alterations, which
may be ameliorated by treatment but not fully restored.
In contrast, shorter and milder courses of hypothyroid-
ism, presumably not being paralleled by irreversible
structural changes, seem to be more accessible to substi-
tution treatment.
Glucose metabolism
In line with findings that general glucose metabolism is
tightly coupled to perfusion [3], preclinical studies gen-
erally reported alterations of glucose metabolism in
hypothyroid conditions [63,69]. More specifically, Bauer
et al. related depressive symptoms in hypothyroidism to
regionally decreased glucose metabolism, particularly in
the peri-genual anterior cingulate cortex region and the
hippocampus [17] in a glucose-PET study. After 3
months of T4 substitution therapy, activity patterns nor-
malized. Circulating TSH levels before initiation of ther-
apy showed a significant positive correlation with
glucose metabolism in the right ACC and negative cor-
relations in the hippocampus. Interestingly, these two
regions express TSH receptors very densely according to
topographic studies in rat and human [70], whereby
suggesting a direct and relevant effect of elevated
TSH levels on the limbic system is of course highly
speculative.
Cognitive and emotional functional changes
In line with the wide range of metabolic, perfusional
and structural implications of the thyroid system, the
literature on functional alterations related to thyroid
diseases is large. Disturbances of the thyroid system,
particularly if leading to a hypothyroid state, may pro-
foundly alter mental functions influencing cognition
and emotions. Severe hypothyroidism may lead to both
severe depression and dementia [71] especially if left
untreated [72].
Neuropsychologically, several cognitive defects in gen-
eral intelligence, psychomotor speed, visual-spatial skills,
working and long-term memory have been observed
ranging from minimal to severe [73-75]. It was sug-
gested that hypothyroid-related memory defects are not
attributable to an attention deficit but rather to specific
retrieval deficits [73,76]. Motor skills, language, inhibi-
tory efficiency, and sustained attention appear to be less
impacted by hypothyroidism [73,75]. Older adults were
more vulnerable to cognitive changes due to hypothyr-
oidism [75].
It is still a matter of discussion as to whether subcli-
nical hypothyroidism is associated with cognitive
impairments. In some studies, patients with subclinical
hypothyroidism performed worse than controls on well
established neuropsychological tests such as the
Wechsler Adult Intelligence Scale or the Wechsler
Memory scale [77,78], while other studies found no
association between subclinical hypothyroidism and
several aspects of cognition [75,79,80]. A consistent
finding among many studies was a specific deficit in
working memory tasks [73]. These neuropsychological
findings were additionally underlined by a functional
MRI (fMRI) study by Zhu et al. [68] who found that
working memory was impaired in patients with subcli-
nical hypothyroidism but not other memory functions.
These impairments were reversible with l-thyroxine
(L-T4) treatment.
Despite clinical evidence of an increased vulnerability
for affective disorders coming along with hypothyroid
states, neurobiological correlates of this disposition are
not systematically investigated yet. This is of particular
interest because a study by Maheu et al. [81] demon-
strated that fMRI could detect greater hippocampal and
amygdala activation in 12 non-depressed adolescent
patients with Cushing’s syndrome, when encoding affec-
tive stimuli (i.e. emotional faces) compared to 22 healthy
controls. A similar pattern of brain activation has pre-
viously been demonstrated in adolescents suffering from
manifest depression in an equivalent paradigm [82].
CushingÂ´s syndrome is defined by hypercortisolemia
and highly associated with prevalence of depressive
symptoms in adults [83] and shows in this respect dis-
tinct parallels to hypothyroidism.
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Conclusions
Hypothyroid states have a multitude of effects on struc-
ture, perfusion and function of the central nervous sys-
tem. Recent research aims to combine modern brain
imaging techniques with years of experience in neurop-
sychological and clinical evaluations of thyroid dysfunc-
tions. The results are encouraging, and the description
of the interactions between thyroid and affective disor-
ders is taking on a new dimension. Nonetheless, the
potential of modern techniques has hardly been
exhausted. For example, non invasive measurements of
brain perfusion like arterial-spin-labeling (ASL) –
already established in characterisation of different cere-
brovascular diseases [84] – would be suitable for trans-
ferring hypotheses about the influence of angiogenesis
[85] from animal models into humans. fMRI in patients
with thyroid diseases of different length and severity
could help to identify functional aberrations such as
memory impairments or altered emotional processing,
which has long been suggested from animal studies.
Structural changes related to myelin, which have been
observed in various animal models, can now be studied
with quantitative T2 or quantitative magnetization
transfer (MT) imaging [86]. Finally diffusion tensor ima-
ging (DTI) [54] can reveal information on white matter
integrity.
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